{"id":"NCT01844115","sponsor":"Forest Laboratories","briefTitle":"Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder","officialTitle":"A Double-Blind, Placebo-Controlled, Flexible-Dose Study of Vilazodone in Patients With Generalized Anxiety Disorder.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04-30","primaryCompletion":"2014-03-31","completion":"2014-03-31","firstPosted":"2013-05-01","resultsPosted":"2019-12-18","lastUpdate":"2019-12-18"},"enrollment":415,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Generalized Anxiety Disorder"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":["Matching 10 mg and 20 mg placebo tablets, once-daily oral administration."]},{"type":"DRUG","name":"Vilazodone","otherNames":["Vilazodone, 20 mg once per day, oral administration, once daily or Vilazodone, 40 mg once daily, oral administration, once daily"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Vilazodone","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD).","primaryOutcome":{"measure":"Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score","timeFrame":"Baseline to Week 8","effectByArm":[{"arm":"Placebo","deltaMin":14.7,"sd":7.41},{"arm":"Vilazodone","deltaMin":11.3,"sd":6.99}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0048"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":36,"countries":["United States"]},"refs":{"pmids":["27486544","27232052"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":202},"commonTop":["Nausea","Diarrhoea","Headache","Dizziness","Dry mouth"]}}